Regulatory Advantages Of Clinical Trials In Canada Versus Australia

Altasciences is an award-winning, forward-thinking, mid-size early phase contract research organization, in Canada and the U.S., offering biopharmaceutical companies of all sizes a proven, flexible approach to early drug development, including preclinical safety testing, clinical pharmacology (Phase I to Phase II), bioanalysis, preclinical to Phase IV), research services, and manufacturing and analytical services.

From lead candidate selection to proof of concept, we offer one-stop integrated formulation, preclinical and clinical manufacturing and analytical services. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements.

Eryn Corriveau, Senior Director of Drug Development and Regulatory Strategy, answers your question about the regulatory advantages of conducting your clinical study in Canada versus Australia.